TrialAnnals of the rheumatic diseases2014

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients.

Brandon W Higgs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.